When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ENTA - Enanta's EDP-305 flunks mid-stage study in bile duct disorder
Enanta Pharmaceuticals Inc.
A Phase 2 clinical trial, INTREPID, evaluating Enanta Pharmaceuticals' (NASDAQ:ENTA) EDP-305 in patients with a bile duct disorder called primary biliary cholangitis (PBC), failed to achieve the primary endpoint of a statistically significant proportion of treated patients experiencing at least a 20% reduction in a liver enzyme called ALP at week 12 versus placebo.
More news on: Enanta Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,